Test aims to spare breast cancer patients unnecessary chemo
NCT ID NCT07379918
Summary
This study is evaluating a genomic test called EndoPredict that helps predict the 10-year risk of breast cancer returning. It aims to see if the test can reliably identify patients with a low risk of recurrence, so they can safely avoid chemotherapy and receive hormone therapy alone. The study will follow 1,000 patients in France for 10 years to see how well the test works in real-world practice.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Saint-Louis
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.